Vyome Holdings, Inc. (HIND)
| Market Cap | 13.27M +249.1% |
| Revenue (ttm) | 152,724 -59.7% |
| Net Income | -10.93M |
| EPS | -2.85 |
| Shares Out | 7.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,337 |
| Open | 1.870 |
| Previous Close | 1.890 |
| Day's Range | 1.810 - 1.920 |
| 52-Week Range | 1.750 - 16.000 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 11.50 (+508.47%) |
| Earnings Date | May 12, 2026 |
About HIND
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5′-monophosphate dehydrogenase enzyme... [Read more]
Financial Performance
In 2025, Vyome Holdings's revenue was $319,714, an increase of 24.43% compared to the previous year's $256,944. Losses were -$10.26 million, 609.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for HIND stock is "Buy." The 12-month stock price target is $11.5, which is an increase of 508.47% from the latest price.
News
Vyome signs exclusive license agreement with Impetis
Vyome (HIND) Holdings announced the signing of an agreement with Impetis Biosciences, a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and…
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (“Impetis”), a TATA Enterprise, that gives...
Vyome initiated with a Buy at Litchfield Hills
Litchfield Hills analyst Theodore O’Neill initiated coverage of Vyome (HIND) with a Buy rating and $8 price target The company’s drug development operating system repurposes an FDA-approved molecule f...
Vyome Holdings presents Phase 2 study results on VT-1953
Vyome Holdings (HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malign...
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026.
Vyome Holdings to present Phase 2 data on VT-1953 at AACR 2026
Vyome Holdings (HIND) will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and…
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical dat...
Vyome Holdings reports FY25 revenue $319.7k vs $246.9k last year
“Vyome is targeting one of the biggest challenges in the world today – inflammation. So many of our medical and mental problems are linked to increased inflammation. We are building…
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase.
Vyome Holdings publishes preclinical VT-1908 data
Vyome Holdings (HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed Journal of Ophthalmic In...
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity.
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare co...
Vyome Holdings funds budget for VT-1953 study
Vyome Holdings (HIND) announced it has funded the budget for its VT-1953 Phase 3 study, which provides the company sufficient capital to fund the estimated costs to release Phase 3…
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results.
Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study.
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LICH LOI with Remus.
Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints
Vyome Holdings (HIND) announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds. VT-1953, an immunomodu...
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome VT-1953 P2 results.
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In ...
Vyome Holdings Earnings Call Transcript: Q3 2025
Reported $5.7M in cash with runway through 2026, a net loss of $9.2M due to one-time merger charges, and lower than expected cash burn. Interim phase two results for VT1953 were positive, and regulatory engagement for VT1908 is planned for 2026.
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings Third Quarter 2025 Earnings Release.
Vyome Holdings files to sell 610K shares of common stock for holders
The company will not receive any of the proceeds from the sale of common stock by the selling stockholders.
Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation
“From 2019 to 2025, the biomarker landscape has seen a surge in strategic collaborations, licensing, and acquisitions, driven by the growing demand for precision medicine, companion diagnostics, and t...
Vyome Holdings Announces Results of Annual Shareholder Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Annual meeting of Vyome Holdings Inc.
Vyome Holdings upgraded to Buy at Maxim on immuno-inflammatory pipeline
As previously reported, Maxim upgraded Vyome Holdings (HIND) to Buy from Hold with a $15 price target after the analyst takes over coverage of the stock, citing opportunities in the…